Persomics is a private life science company specializing in genetic research, with locations in Boston, MA, Cupertino, CA, and Gothenburg, Sweden.

The company’s aim is to simplify and expedite the process of discovering the basis of disease, and it has established a particular phenotypic screening kit that it uses for this purpose.

These kits facilitate the interrogation of thousands of genes in parallel, and therefore pertain to human genome, pharmaceutical and disease model research.

By 2013 the drug discovery market had begun shifting from the single to the multi-target paradigm, of which Persomics’ technology is a part.

[1] Today phenotypic screening is enjoying a significant resurgence as part of the portfolio of drug discovery strategies leveraged at most companies.

[6] Persomics was founded in 2014, when it established itself as part of the Gatehouse Park biohub in Waltham, Massachusetts, which also houses AstraZeneca.